Regeneron | Pushing the Bounds of Science
Discover how Regeneron (NASDAQ: REGN) harmonizes biology and technology to create life-changing medicines. Join our team and explore clinical trials.
Regeneron Pharmaceuticals - Wikipedia
Regeneron has developed aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a …
Investor Relations | Regeneron Pharmaceuticals Inc.
3 days ago · Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Learn more …
PUSH THE BOUNDS OF SCIENCE - Regeneron
Regeneron is a leading science and technology company dedicated to inventing, developing and commercializing life-transforming treatments for serious diseases.
Clinical Trials Home | Regeneron Pharmaceuticals
Search for a Regeneron clinical trial based on condition, keyword, and location. Explore comprehensive information on our highlighted trials to learn more.
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
10 hours ago · Regeneron swooped in to save the struggling 23andMe last month, bidding $256 million to acquire the genetic testing company in a bankruptcy auction. Aside from the testing …
About Regeneron | Our Company
Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, …
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm …
Jun 2, 2025 · When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the …
Full Awards: High school scientists win more than $9M at Regeneron …
May 17, 2024 · Regeneron and Society for Science are pleased to present an award of $75,000 to the top First Place project. The George D. Yancopoulos Innovator Award recognizes the best …
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic …
Jun 2, 2025 · New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China. Phase 2 …